相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Dual-tracer PET/CT-targeted, mpMRI-targeted, systematic biopsy, and combined biopsy for the diagnosis of prostate cancer: a pilot study
Dong-Xu Qiu et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)
Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer
Hina Shah et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2022)
Comparison of 68Ga-PSMA-617 PET/CT and 68Ga-RM2 PET/CT in patients with localized prostate cancer candidate for radical prostatectomy: a prospective, single arm, single center, phase II study
Romain Schollhammer et al.
JOURNAL OF NUCLEAR MEDICINE (2022)
Genomic and phenotypic heterogeneity in prostate cancer
Michael C. Haffner et al.
NATURE REVIEWS UROLOGY (2021)
E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET
Francesco Ceci et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
PSMA- and GRPR-Targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer
Lucia Baratto et al.
JOURNAL OF NUCLEAR MEDICINE (2021)
Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review
Mathieu Gauthe et al.
JOURNAL OF CLINICAL MEDICINE (2021)
GRPr Antagonist 68Ga-SB3 PET/CT Imaging of Primary Prostate Cancer in Therapy-Naive Patients
Ingrid L. Bakker et al.
JOURNAL OF NUCLEAR MEDICINE (2021)
[68Ga]Ga-iPSMA-Lys3-Bombesin: Biokinetics, dosimetry and first patient PET/CT imaging
Belen Rivera-Bravo et al.
NUCLEAR MEDICINE AND BIOLOGY (2021)
Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis
Marlon Perera et al.
EUROPEAN UROLOGY (2020)
Ga-68-PSMA I&T PET/CT for primary staging of prostate cancer
Wojciech Cytawa et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [177Lu]Lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer
Jens Kurth et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma
Geert J. L. H. van Leenders et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2020)
Voxel-based comparison of [68Ga]Ga-RM2-PET/CT and [68Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer
Thomas Franz Fassbender et al.
EJNMMI RESEARCH (2020)
Radiopharmaceutical therapy in cancer: clinical advances and challenges
George Sgouros et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Novel imaging in prostate cancer
Orestis Porfyris et al.
UROLOGY ANNALS (2020)
Accuracy of [68Ga]Ga-RM2-PET/CT for diagnosis of primary prostate cancer compared to histopathology
Thomas F. Fassbender et al.
NUCLEAR MEDICINE AND BIOLOGY (2019)
Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer
Alec Paschalis et al.
EUROPEAN UROLOGY (2019)
Comparison of the radiolabeled PSMA-inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2 in primary prostate cancer samples
Romain Schollhammer et al.
EJNMMI RESEARCH (2019)
Diagnostic performance of 68Ga-PSMA PET/CT in the detection of prostate cancer prior to initial biopsy: comparison with cancer-predicting nomograms
Jingliang Zhang et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer
Karim A. Touijer et al.
EUROPEAN UROLOGY ONCOLOGY (2019)
Positron Emission Tomography Imaging of the Gastrin-Releasing Peptide Receptor with a Novel Bombesin Analogue
Joseph Lau et al.
ACS OMEGA (2019)
Immunohistochemical Validation of PSMA Expression Measured by Ga-68-PSMA PET/CT in Primary Prostate Cancer
Nadine Woythal et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
PET Using a GRPR Antagonist Ga-68-RM26 in Healthy Volunteers and Prostate Cancer Patients
Jingjing Zhang et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Update on 18F-Fluciclovine PET for Prostate Cancer Imaging
Ephraim E. Parent et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls
Michael S. Hofman et al.
RADIOGRAPHICS (2018)
Consensus on molecular imaging and theranostics in prostate cancer
Stefano Fanti et al.
LANCET ONCOLOGY (2018)
First in-human radiation dosimetry of the gastrin-releasing peptide (GRP) receptor antagonist Ga-68-NODAGA-MJ9
Silvano Gnesin et al.
EJNMMI RESEARCH (2018)
Theranostic Perspectives in Prostate Cancer with the Gastrin Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results
Berthold A. Nock et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
68Ga-PSMA-11 PET/CT in Newly Diagnosed Carcinoma of the Prostate: Correlation of Intraprostatic PSMA Uptake with Several Clinical Parameters
Stefan A. Koerber et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
The role of 68Ga-PSMA-I&T PET/CT in the pretreatment staging of primary prostate cancer
Danielle P. Meyrick et al.
NUCLEAR MEDICINE COMMUNICATIONS (2017)
Evaluation of Prostate Cancer with 11C- and 18F-Choline PET/CT: Diagnosis and Initial Staging
Sascha Nitsch et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Bombesin-Targeted PET of Prostate Cancer
Rosalba Mansi et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Dosimetry and First Clinical Evaluation of the New 18F-Radiolabeled Bombesin Analogue BAY 864367 in Patients with Prostate Cancer
Bert-Ram Sah et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26
Zohreh Varasteh et al.
NUCLEAR MEDICINE AND BIOLOGY (2015)
Overdiagnosis and Overtreatment of Prostate Cancer
Stacy Loeb et al.
EUROPEAN UROLOGY (2014)
Targeting Neuropeptide Receptors for Cancer Imaging and Therapy: Perspectives with Bombesin, Neurotensin, and Neuropeptide-Y Receptors
Clement Morgat et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer
Matthias Eder et al.
PROSTATE (2014)
Positron Emission Tomography (PET) Imaging of Prostate Cancer with a Gastrin Releasing Peptide Receptor Antagonist - from Mice to Men
Gesche Wieser et al.
THERANOSTICS (2014)
In Vivo Imaging of Prostate Cancer Using [68Ga]-Labeled Bombesin Analog BAY86-7548
Esa Kahkonen et al.
CLINICAL CANCER RESEARCH (2013)
Targeting GRPR in urological cancers -from basic research to clinical application
Rosalba Mansi et al.
NATURE REVIEWS UROLOGY (2013)
Unexpected Sensitivity of sst2 Antagonists to N-Terminal Radiometal Modifications
Melpomeni Fani et al.
JOURNAL OF NUCLEAR MEDICINE (2012)
Profiling gastrin-releasing peptide receptor in prostate tissues: Clinical implications and molecular correlates
Marc Beer et al.
PROSTATE (2012)
Immunohistochemical analysis of gastrin-releasing peptide receptor (GRPR) and possible regulation by estrogen receptor βcx in human prostate carcinoma
S. Nagasaki et al.
NEOPLASMA (2012)
F-18-Labeled GRPR Agonists and Antagonists: A Comparative Study in Prostate Cancer Imaging
Min Yang et al.
THERANOSTICS (2011)
Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors
Mihaela Ginj et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
分享论文
